表紙
市場調查報告書

腎細胞癌症:治療藥市場預測與分析 (到2028年)

Renal Cell Carcinoma: Global Drug Forecast and Market Analysis to 2028

出版商 GlobalData 商品編碼 929724
出版日期 內容資訊 英文 160 Pages
訂單完成後即時交付
價格
腎細胞癌症:治療藥市場預測與分析 (到2028年) Renal Cell Carcinoma: Global Drug Forecast and Market Analysis to 2028
出版日期: 2020年02月28日內容資訊: 英文 160 Pages
簡介

腎細胞癌症(RCC)在成人的腎臟癌症中是最常見的類型,佔所有腎臟癌症病例的90∼95%。全世界中,RCC是男性第6大,女性第10大診斷數高的癌症。RCC,以不同的遺傳的及有代謝缺陷的不平均的腫瘤群構成。目前,對轉移性RCC(mRCC)的治療達成完全成功(CR)的患者非常少數。可是,根據過去15年治療的大幅進步,無惡化生存期期間(PFS)和全生存期間(OS)大幅度改善。

本報告提供全球主要8個國家 (8MM) 的腎細胞癌症 (RCC) 治療藥的市場相關分析,疾病概要和流行病學的背景,發病數量、患病人數趨勢預測 (今後10年份),臨床實驗的進展,已上市/臨床實驗中主要的治療藥,目前市場未滿足需求,主要企業的簡介,全球/主要國家的市場趨勢預測等調查。

第1章 目錄

第2章 腎細胞癌症 (RCC):摘要整理

第3章 簡介

第4章 疾病概要

  • 病因與病理學
    • 病因
    • 病理生理學
  • 預後模式
  • 生物標記
  • 臨床階段

第5章 流行病學

  • 病的背景
  • 與危險因素並存症
  • 全球過去趨勢
  • 預測手法
    • 資訊來源
    • 預測的前提條件與手法:總人口
    • 預測的前提條件與手法:RCC的已受診發病數量
    • 預測的前提條件與手法:RCC的已受診發病數量,診斷時的各病期
    • 預測的前提條件與手法:RCC的已受診發病數量,各預後模式
    • 預測的前提條件與手法:RCC的已受診發病數量,各生物標記
    • 預測的前提條件與手法:RCC的5年、10年患病人數
  • 腎細胞癌症 (RCC)的流行病學的預測 (2018∼2028年)
    • RCC的已受診發病數量
    • RCC的已受診發病數量:各年齡
    • RCC的已受診發病數量:男女
    • RCC的已受診發病數量:診斷時的各病期
    • RCC的已受診發病數量:各預後模式
    • RCC的5年患病人數
    • RCC的10年患病人數
  • 討論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第6章 疾病管理

第7章 競爭評估

第8章 未滿足需求與市場機會分析

第9章 開發平台評估

第10章 現在、未來市場參與企業

第11章 市場未來展望

第12章 附錄

目錄
Product Code: GDHC191PIDR

Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, making up 90-95% of all kidney cancer cases. Globally, RCC represents the sixth most frequently diagnosed cancer in men and 10th in women. RCC consists of a heterogeneous group of tumors with distinct genetic and metabolic defects. The major histologic RCC subtype is ccRCC, which represents 80-95% of cases (as shown in Table 2). Other forms of the disease, usually referred as non-clear cell RCC (nccRCC), include papillary RCC (PRCC), chromophobe RCC (ChRCC), translocation carcinoma, medullary carcinoma, and collecting duct carcinoma. At present, metastatic RCC (mRCC) is considered incurable, with only a small minority of patients achieving a complete response (CR) to treatment. However, major advances in the treatment landscape within the past 15 years have significantly improved progression-free survival (PFS) and overall survival (OS).

GlobalData is expecting a total of 7 new entrants to launch over the forecast period in the 8MM from 2018-2028 while specific marketed agents are expected to undergo label expansion. The competition will be particularly fierce in renal cell carcinoma, immune checkpoint inhibitors and combinations thereof competing for market share in the adjuvant setting and in fist-line treatment of metastatic RCC. No drugs are currently in late development for nccRCC leaving the treatment of that population an unmet need within the forecast period.

KEY QUESTIONS ANSWERED

  • Seven late-stage pipeline agents are going to enter the renal cell carcinoma market from 2018 onwards. What impact will these agents have on the market?
  • Which of these drugs will have the highest peak sales, and why?
  • What are the current unmet needs in renal cell carcinoma, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
  • What is the market outlook in the 8MM from 2018-2028? Consideration of major patent expiries, launch of new premium priced agents and expected label expansions.
  • What are the main corporate trends? Who are the current and future players?

Scope

  • Overview of renal cell carcinoma including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline renal cell carcinoma market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting renal cell carcinoma therapeutics sales in the 8MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global renal cell carcinoma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global renal cell carcinoma therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global renal cell carcinoma market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the renal cell carcinoma therapeutics market from 2018-2028.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Renal Cell Carcinoma: Executive Summary

  • 2.1 The RCC market is expected to grow to $6.4B in 2028
  • 2.2 The Development of Combination Treatments Is the Pillar of Corporate Strategies in RCC
  • 2.3 Opportunities Remain for More Effective Therapies and Treatments for nccRCC
  • 2.4 The RCC Pipeline Is Diverse, Comprising Label Expansions and Novel Mechanisms of Action
  • 2.5 What Do Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
  • 4.2 Prognostic models
  • 4.3 Biomarkers
  • 4.4 Clinical Staging

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
  • 5.4 Forecast Methodology
    • 5.4.1 Sources
    • 5.4.2 Forecast Assumptions and Methods, Population
    • 5.4.3 Forecast Assumptions and Methods, Diagnosed Incident Cases of RCC
    • 5.4.4 Forecast Assumptions and Methods, Diagnosed Incident Cases of RCC by Stage at Diagnosis
    • 5.4.5 Forecast Assumptions and Methods, Diagnosed Incident Cases of RCC by Prognostic Model
    • 5.4.6 Forecast Assumptions and Methods, Diagnosed Incident Cases of RCC by Biomarkers
    • 5.4.7 Forecast Assumptions and Methods, Five-Year and 10-Year Diagnosed Prevalent Cases of RCC
  • 5.5 Epidemiological Forecast for RCC (2018-2028)
    • 5.5.1 Diagnosed Incident Cases of RCC
    • 5.5.2 Age-Specific Diagnosed Incident Cases of RCC
    • 5.5.3 Sex-Specific Diagnosed Incident Cases of RCC
    • 5.5.4 Diagnosed Incident Cases of RCC by Stage at Diagnosis
    • 5.5.5 Diagnosed Incident Cases of RCC Stage IV by Prognostic Model
    • 5.5.6 Diagnosed Incident Cases of RCC Stage IV by Biomarkers
    • 5.5.7 Five-Year Diagnosed Prevalent Cases of RCC
    • 5.5.8 10-Year Diagnosed Prevalent Cases of RCC
  • 5.6 Discussion
    • 5.6.1 Epidemiological Forecast Insight
    • 5.6.2 Limitations of the Analysis
    • 5.6.3 Strengths of the Analysis

6 Disease Management

7 Competitive Assessment

8 Unmet Needs and Opportunity Assessment

9 Pipeline Assessment

10 Current and Future Players

11 Market Outlook

12 Appendix

List of Tables

  • Table 1: RCC: Key Metrics in the 8MM
  • Table 2: Classifications of RCC
  • Table 3: TNM and Staging Classification System for RCC
  • Table 4: Risk Factors and Comorbidities for RCC
  • Table 5: RCC Clinical Stages at Diagnosis
  • Table 6: Treatment Guideli

List of Figures

  • Figure 1: Global Sales Forecast by Country for RCC in 2018 and 2028
  • Figure 2: Analysis of the Company Portfolio Gap in RCC During the Forecast Period
  • Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expect